Pharma News

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer, according to ...

Genmab has received approval from the Japan’s Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat advanced or recurrent cervical cancer that progressed on or follo...

The US Food and Drug Administration (FDA) has granted Fast Track designation to the antibody drug conjugate XMT-1660, which has been given an international nonproprietary name of emiltatug led...

Fitusiran offers a 90% reduction in bleeding rates for hemophilia A or B with less frequent dosing than existing options. Phase 3 ATLAS trials showed significant efficacy, with many participants e...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to secure ...

German pharmaceutical company Grünenthal has announced that the US Food and Drug Administration (FDA) has awarded it Breakthrough Therapy Designation (BTD) for its investigational non...

PHILADELPHIA and VANCOUVER, British Columbia, -- BriaCell Therapeutics Corp., a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announc...

Cell and gene therapy (CGT) has emerged as a transformative frontier in medical science, offering potential cures for previously untreatable conditions, including various haematological and ge...

Pharming Group has announced that the first patient has been dosed in a phase 2 clinical trial evaluating leniolisib (sold under the brand name Joenja) in common variable immunodeficiency (...

Allegro Biotech has announced that hydrocelin (ALG-001), its injectable microparticle hydrogel, showed no signs of toxicity in two preclinical studies. Allegro is a biomedical company that dev...

Apitegromab remains on track to be the first and only muscle-targeted treatment for people living with Spinal Muscular Atrophy

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and commercialisation of the former’s ESK-001 for dermatological indications in Ja...